We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Fractional Flow Reserve Computed Tomography

The Cardiovascular Phenomics Core (CPC) was a partner in the NXT Trial that led to Food and Drug Administration approval of HeartFlow fractional flow reserve computed tomography (FFR-CT) analysis – the first of its kind.

The CPC provided both FFR and quantitative coronary analysis (QCA) for the trial.

We played a key role in the first in U.S. clinical implementation of FFR-CT technology, which took place at University Hospitals Cleveland Medical Center in Cleveland, Ohio.